Full Press Release Details
Shao Lee-Lin M.D., Ph.D., brings more than 25 years of biopharmaceutical leadership experience to Cue Biopharma. Prior to joining Cue, Dr. Lin served as Chief Executive Officer and chairman of the board of directors of AZEO BIO, Inc., a biopharmaceutical company she founded in July 2024 and incorporated in July 2025. Dr. Lin was Founder, Chief Executive Officer and director of ACELYRIN, a publicly traded biopharmaceutical company, from July 2020 until May 2024. Earlier in her career, Dr. Lin served as Executive Vice President, Research and Development and Chief Scientific Officer at Horizon Therapeutics and held executive leadership positions at AbbVie, Gilead Sciences and Amgen. Dr. Lin also served on the board of directors of ACELYRIN, Surrozen, Principia Biopharma and Third Harmonic Bio. Dr. Lin received her bachelor’s degree in chemical engineering and biochemistry and graduated magna cum laude from Rice University. She holds an M.D. and Ph.D. from The Johns Hopkins University School of Medicine.